These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2719897)

  • 1. Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy.
    Belec L; Larrey D; De Cremoux H; Tinel M; Louarn F; Pessayre D; Gherardi R
    Br J Clin Pharmacol; 1989 Mar; 27(3):387-90. PubMed ID: 2719897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of dextromethorphan O-demethylation in man.
    Küpfer A; Schmid B; Pfaff G
    Xenobiotica; 1986 May; 16(5):421-33. PubMed ID: 3739367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
    Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
    Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man.
    Mortimer O; Lindström B; Laurell H; Bergman U; Rane A
    Br J Clin Pharmacol; 1989 Feb; 27(2):223-7. PubMed ID: 2713216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis.
    Henthorn TK; Benitez J; Avram MJ; Martinez C; Llerena A; Cobaleda J; Krejcie TC; Gibbons RD
    Clin Pharmacol Ther; 1989 Mar; 45(3):328-33. PubMed ID: 2920506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man.
    Zysset T; Zeugin T; Küpfer A
    Biochem Pharmacol; 1988 Aug; 37(16):3155-60. PubMed ID: 3401246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients.
    Larrey D; Tinel M; Amouyal G; Freneaux E; Berson A; Fouin-Fortunet H; Babany G; Letteron P; Iglicki F; Slama JL
    J Hepatol; 1989 Mar; 8(2):158-64. PubMed ID: 2715619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism.
    Roy SD; Hawes EM; Hubbard JW; McKay G; Midha KK
    Lancet; 1984 Dec; 2(8416):1393. PubMed ID: 6150386
    [No Abstract]   [Full Text] [Related]  

  • 9. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.
    Schmid B; Bircher J; Preisig R; Küpfer A
    Clin Pharmacol Ther; 1985 Dec; 38(6):618-24. PubMed ID: 4064464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of dextromethorphan oxidation in a French population.
    Larrey D; Amouyal G; Tinel M; Letteron P; Berson A; Labbe G; Pessayre D
    Br J Clin Pharmacol; 1987 Nov; 24(5):676-9. PubMed ID: 3435696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.
    Küpfer A; Schmid B; Preisig R; Pfaff G
    Lancet; 1984 Sep; 2(8401):517-8. PubMed ID: 6147572
    [No Abstract]   [Full Text] [Related]  

  • 12. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children.
    Evans WE; Relling MV; Petros WP; Meyer WH; Mirro J; Crom WR
    Clin Pharmacol Ther; 1989 May; 45(5):568-73. PubMed ID: 2721111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.
    Larrey D; Babany G; Tinel M; Freneaux E; Amouyal G; Habersetzer F; Letteron P; Pessayre D
    Br J Clin Pharmacol; 1989 Sep; 28(3):297-304. PubMed ID: 2789923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.
    Irshaid YM; al-Hadidi HF; Latif A; Awwadi F; al-Zoubi M; Rawashdeh NM
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):301-7. PubMed ID: 9074894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of dextromethorphan metabolizer phenotype in healthy volunteers.
    Hildebrand M; Seifert W; Reichenberger A
    Eur J Clin Pharmacol; 1989; 36(3):315-8. PubMed ID: 2744072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The polymorphic metabolism of dextromethorphan.
    Woodworth JR; Dennis SR; Moore L; Rotenberg KS
    J Clin Pharmacol; 1987 Feb; 27(2):139-43. PubMed ID: 3680565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
    Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
    Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral neuropathies during treatment with almitrine: report of 46 cases.
    Bouche P; Lacomblez L; Leger JM; Chaunu MP; Ratinahirana H; Brunet P; Hauw JJ; Cathala HP; Laplane D
    J Neurol; 1989 Jan; 236(1):29-33. PubMed ID: 2536801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debrisoquine and dextromethorphan phenotyping and antidepressant treatment.
    Perault MC; Bouquet S; Bertschy G; Vandel S; Chakroun R; Guibert S; Vandel B
    Therapie; 1991; 46(1):1-3. PubMed ID: 2020918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
    Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.